Brian Birchler
CIK: 0001970151
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IONIS PHARMACEUTICALS INC
Discretionary Trading P&L
Holdings
Transaction History (26 total)
- Aug 31, 2026IONS
IONIS PHARMACEUTICALS INC
Other(J)Direct58 shares at avg. $51.31$3K - Apr 16, 2026IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct973 shares at avg. $75.04$73K - Apr 15, 2026IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct1.9K shares- - Feb 27, 2026IONS
IONIS PHARMACEUTICALS INC
Other(J)Direct351 shares at avg. $48.87$17K - Jan 30, 2026IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct6.2K shares at avg. $83.03$513K - Jan 29, 2026IONS
IONIS PHARMACEUTICALS INC
Award(A)Direct12K shares- - Jan 16, 2026IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct8.5K shares at avg. $75.11$637K - Jan 15, 2026IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Unit
9.7K shares- - Jan 15, 2026IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct20.1K shares- - Jan 15, 2026IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectPerformance Restricted Stock Units
25.8K shares- - Jan 2, 2026IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectNon-Qualified Stock Option (right to buy)
19.4K shares- - Nov 6, 2025IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct8K shares at avg. $76.17$609K - Oct 15, 2025IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct12.4K shares at avg. $53.77$668K - Oct 15, 2025IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct12.4K shares at avg. $72.23$897K - Oct 14, 2025IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct11.5K shares at avg. $72.03$827K - Oct 14, 2025IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct11.5K shares at avg. $53.77$617K - Aug 29, 2025IONS
IONIS PHARMACEUTICALS INC
Other(J)Direct166 shares at avg. $27.71$5K - Apr 16, 2025IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct680 shares at avg. $28.37$19K - Apr 15, 2025IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct1.9K shares- - Feb 28, 2025IONS
IONIS PHARMACEUTICALS INC
Other(J)Direct414 shares at avg. $28.21$12K - Jan 16, 2025IONS
IONIS PHARMACEUTICALS INC
Sale(S)Direct5.4K shares at avg. $32.70$177K - Jan 15, 2025IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectPerformance Restricted Stock Units
22K shares- - Jan 15, 2025IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectRestricted Stock Unit
33K shares- - Jan 15, 2025IONS
IONIS PHARMACEUTICALS INC
Exercise(M)Direct14.3K shares- - Jan 2, 2025IONS
IONIS PHARMACEUTICALS INC
Award(A)DirectNon-Qualified Stock Option (right to buy)
22K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 31, 2026 | IONS IONIS PHARMACEUTICALS INC | Other(J) | 58 | $51.31 | $2,976 | Direct |
| Apr 16, 2026 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 973 | $75.04 | $73,016 | Direct |
| Apr 15, 2026 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 1,875 | - | $0 | Direct |
| Feb 27, 2026 | IONS IONIS PHARMACEUTICALS INC | Other(J) | 351 | $48.87 | $17,152 | Direct |
| Jan 30, 2026 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 6,179 | $83.03 | $513,048 | Direct |
| Jan 29, 2026 | IONS IONIS PHARMACEUTICALS INC | Award(A) | 11,991 | - | $0 | Direct |
| Jan 16, 2026 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 8,480 | $75.11 | $636,933 | Direct |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | Award(A) Restricted Stock Unit | 9,675 | - | - | Direct |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 20,089 | - | $0 | Direct |
| Jan 15, 2026 | IONS IONIS PHARMACEUTICALS INC | Award(A) Performance Restricted Stock Units | 25,800 | - | - | Direct |
| Jan 2, 2026 | IONS IONIS PHARMACEUTICALS INC | Award(A) Non-Qualified Stock Option (right to buy) | 19,350 | - | - | Direct |
| Nov 6, 2025 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 8,000 | $76.17 | $609,379 | Direct |
| Oct 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 12,425 | $53.77 | $668,092 | Direct |
| Oct 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 12,425 | $72.23 | $897,398 | Direct |
| Oct 14, 2025 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 11,475 | $72.03 | $826,589 | Direct |
| Oct 14, 2025 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 11,475 | $53.77 | $617,011 | Direct |
| Aug 29, 2025 | IONS IONIS PHARMACEUTICALS INC | Other(J) | 166 | $27.71 | $4,600 | Direct |
| Apr 16, 2025 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 680 | $28.37 | $19,292 | Direct |
| Apr 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 1,875 | - | - | Direct |
| Feb 28, 2025 | IONS IONIS PHARMACEUTICALS INC | Other(J) | 414 | $28.21 | $11,680 | Direct |
| Jan 16, 2025 | IONS IONIS PHARMACEUTICALS INC | Sale(S) | 5,400 | $32.70 | $176,580 | Direct |
| Jan 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Award(A) Performance Restricted Stock Units | 22,000 | - | - | Direct |
| Jan 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Award(A) Restricted Stock Unit | 33,000 | - | - | Direct |
| Jan 15, 2025 | IONS IONIS PHARMACEUTICALS INC | Exercise(M) | 14,283 | - | $0 | Direct |
| Jan 2, 2025 | IONS IONIS PHARMACEUTICALS INC | Award(A) Non-Qualified Stock Option (right to buy) | 22,000 | - | - | Direct |
1-25 of 26 transactions
About Birchler Brian
Birchler Brian (SEC CIK 0001970151) files insider reports with the SEC as EVP, Corp and Development Ops of IONIS PHARMACEUTICALS INC (IONS).
Signal8 holds 14 ownership filings by Birchler Brian, all Form 4s, filed between Sep 4, 2024 and Sep 2, 2026. Those filings report 26 transactions, from Aug 30, 2024 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Birchler Brian's filings is in CARLSBAD, CA.
Recent filings by Birchler Brian
- Aug 31, 2026: Other transaction of IONS shares (Form 4, code J).
- Apr 16, 2026: Open-market sale of IONS shares (Form 4, code S).
- Apr 15, 2026: Option exercise of IONS shares (Form 4, code M).
- Feb 27, 2026: Other transaction of IONS shares (Form 4, code J).
- Jan 30, 2026: Open-market sale of IONS shares (Form 4, code S).
Other insiders filing for IONIS PHARMACEUTICALS INC (IONS)
- Devers Shannon L., EVP, Chief Human Resources Ofc
- Swayze Eric, EVP Research
- BENNETT C FRANK, EVP, Chief Scientific Officer
- O'NEIL PATRICK R., EVP CLO & General Counsel
- Monia Brett P, Chief Executive Officer
- Hayden Michael R, Director